Biomerica, Inc.
BMRAHealthcareNASDAQMedical Devices · Last scanned Oct 26, 2026
Scan Results
Daily timeframePart of the healthcare sector, Biomerica, Inc. (BMRA) is listed under Medical Devices. At a $7.7M market cap, Biomerica, Inc. ranks as a micro-cap company within healthcare. The company offers diagnostic test kits are used to analyze blood, urine, nasal, or fecal material from patients to aid in the diagnosis of diseases, food intolerances, and other medical conditions, as well as detect and measure the presence and levels of specific bacteria, hormones, antibodies, antigens, and other substances that may exist in the human body at extremely low concentrations through clinical laboratories and in point-of-care settings, including physicians' offices and over-the-counter channels.
Market Cap
$7.7M
Beta
0.38
P/E (TTM)
—
P/E (Fwd)
4.31
EPS (TTM)
$-1.64
EPS (Fwd)
$0.39
ROE
-113.8%
ROA
-45.5%
Cash
$2.7M
Total Debt
$2.3M
Free CF
-$1.6M
52W Change
-43.2%
Annual Financials
Cash vs Debt
Where BMRA stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, BMRA finished 12.87% below its 150-day moving average ($2.02) and 15.79% below its 200-day moving average ($2.09). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BMRA overbought or oversold?
At the October 20, 2026 close, BMRA's RSI(14) was 20.0, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $2.7M in cash and $2.3M in debt, BMRA maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$1.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -113.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $5.3M (2023) to $4.5M (2026), a 17% decline worth watching.
With a beta below 0.7, Biomerica, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing BMRA.